A single case study of punarnavadi kashay and nirocil in hepatitis c viral load

Array

Abstract

Hepatitis C virus infection is the most common blood borne infection, its prevalence reaching upto 170 million worldwide. Most HCV infection persist and about 30% of the individuals with persistent infection develop chronic liver disease, including liver cirrhosis and hepatocellular carcinoma. Although HCV is curable, and antiviral HCV treatment leading to viral eradication reduces liver related morbidity and mortality ,treatment with pegylated interferone plus ribavarin is burdensome ,toxic, expensive, and ineffective for half of those who attempt the therapy. Clinical presentation of HCV shows jaundice, stomach pain, loss of appetite, Nausea, fatigue, myalgia, etc. To counter these entities, drugs having anti-viral and hepatoprotective activity should be administered .In present study 57 yrs old male was enrolled who was infected by HCV prior to our consulting. He was administered Punarnavadi kashay with gomutra in a dose of 80ml into 2 divided doses with warm water after food and Tab Nirocil in a dose of 3 tablets thrice a day before food. Biochemical parameters like Hepatitis C Virus RNA Quantitative analysis was done before and at the end of the trial. Observed results were graded on 4 grade scale and were analyzed before and after the follow-up of 1 month interval for 5 months. Study drug was found to be effective in alleviating most of the symptoms along with desired changes in biochemical markers. To conclude it more firmly, specific targeted study has to be conducted with required modulations.